课题基金 / 基金详情

Core-002

Core-002
核心002
批准号:
10822793
负责人:
Kristina De Paris
金额:
$54.19万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-04-01 至 2025-03-31
关键词:

项目摘要

项目成果

Kristina De Paris的其他基金

相似基金

相关文献

中文摘要
翻译
集成系统免疫学核心(ISIC/Core 2)
英文摘要
ABSTRACT – Integrated Systems Immunology Core (ISIC/Core 2) There is a critical and urgent need for a HIV vaccine that can induce protective immunity prior to or around the time of sexual debut. Our Program seeks to achieve this goal, and the Integrated Systems Immunology Core (ISIC) supports the overall mission by establishing a joint, unified resources for high-content data generation, data warehousing, analysis and dissemination to the scientific community. Specifically, the Integrated Systems Immunology Core focusses on providing single cell Immune-response measurements, microbiome analysis and data curation to both Projects and the NHP Core. As a data generation and management hub, the ISIC also plays a central role in integration and interpretation of results, hosting both quantitative and microbiome technical working groups to streamline these processes. The Core will collaborate with the Administrative Core to ensure rigor and reproducibility of results and effective implementation of systems biology approaches to achieve the overall goals of this HIVRAD grant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core C: B Cell Core
Core A: Administrative Core
Project 1: The impact of innate immune responses on the development of broadly neutralizing antibodies by vaccination
Project 2: Microbial determinants of HIV broadly-neutralizing antibody precursor induction in infants
国内基金
海外基金
Zn(002)晶面锌合金负极制备/运行稳定化全流程设计及机制研究
  • 批准号:
    22578113
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2025
  • 负责人:
    何章兴
  • 依托单位:
锌粉(002)晶面定向调控及其负极性能强化机理研究
  • 批准号:
    2025JJ70625
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    曹鹏辉
  • 依托单位:
Uc002jit.1调控DNA损伤修复诱导AML干细胞化疗耐药的机制及干预策略研究
  • 批准号:
    82404736
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2024
  • 负责人:
    李丁
  • 依托单位:
新型核素偶联药载体JBN002-DOTA的开发及其在肿瘤诊疗中的应用
  • 批准号:
    82373174
  • 项目类别:
    面上项目
  • 资助金额:
    60万元
  • 批准年份:
    2023
  • 负责人:
    杨杰
  • 依托单位: